Plain-English translation of NCT05538208 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Lupus Nephritis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing (MMF) — a medication that helps control lupus-related kidney disease — using two different dosing approaches. One approach doses the medication based on body size (the standard way), while the other uses blood tests to personalize the dose for each patient. The study wants to see which approach works better and is safer for young people with lupus kidney disease.
Lupus can attack the kidneys, causing serious damage and kidney failure if not treated well. Doctors want to find the best way to dose this medication so more young patients can get better kidney function and avoid long-term kidney damage.
You likely qualify if…
You likely don't qualify if…
You will take twice daily for up to 53 weeks, with your dose determined by one of two methods (either by your body size or by personalized blood tests). The study has two parts: the first 26 weeks focus on how well the medication works, and the second 26 weeks allow doctors to adjust your treatment based on your response. You'll attend regular study visits, have blood tests to check your kidney function, and use a smartphone app to help track your medication and health.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
United States